M. Weinkauf

The proteasome inhibitor bortezomib targets cell cycle and apoptosis and acts synergistically in a sequence-dependent way with chemotherapeutic agents in mantle cell lymphoma

W. Hiddemann, A. Pastore, M. Dreyling, 2012, Annals of Hematology.

2‐D PAGE‐based comparison of proteasome inhibitor bortezomib in sensitive and resistant mantle cell lymphoma

A. Rosenwald, W. Hiddemann, A. Pastore, 2009, Electrophoresis.

Cell Cycle Dysregulation Represents an Early Effect of the Proteasome Inhibitor Bortezomib in Mantle Cell Lymphoma.

W. Hiddemann, M. Dreyling, O. Weigert, 2004 .

Combination of hyperthermia and bortezomib results in additive killing in mantle cell lymphoma cells

R. Issels, A. Pastore, M. Dreyling, 2009, International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group.

Differential regulation patterns of the anti‐CD20 antibodies obinutuzumab and rituximab in mantle cell lymphoma

W. Hiddemann, M. Dreyling, V. Jurinovic, 2015, British journal of haematology.

Proteome‐ and microarray‐based expression analysis of lymphoma cell lines identifies a p53‐centered cluster of differentially expressed proteins in mantle cell and follicular lymphoma

W. Hiddemann, M. Dreyling, Marc Weinkauf, 2007, Electrophoresis.

Combined RNA-expression and 2D-PAGE-screening identifies comprehensive interaction networks affected after bortezomib or enzastaurin exposure of mantle cell lymphoma.

A. Rosenwald, M. Dreyling, E. Hartmann, 2010, Talanta.

3’UTR mediated regulation of the cyclin D1 proto-oncogene

C. Buske, A. Pastore, M. Dreyling, 2009, Cell cycle.

Sample pooling in 2‐D gel electrophoresis: A new approach to reduce nonspecific expression background

W. Hiddemann, M. Dreyling, M. Weinkauf, 2006, Electrophoresis.